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Statement of translational relevance: 
The secondary T790M mutation in EGFR is the most frequent cause of acquired 
resistance to the reversible EGFR tyrosine kinase inhibitors (EGFR-TKIs), 
gefitinib and erlotinib, in lung cancer. Irreversible EGFR-TKIs are potentially 
useful agents to control the reversible EGFR-TKI-resistance of lung cancer. 
Although some of these inhibitors are in clinical development and early signs of 
success have been reported in lung cancer patients who were refractory to the 
reversible EGFR-TKI, it is clear that resistance may also develop against this 
class of inhibitors. 
In this study, we demonstrated that hepatocyte growth factor (HGF) 
reduced susceptibility to irreversible EGFR-TKI in lung cancer cells with the 
secondary T790M mutation in EGFR. We further demonstrated that HGF-MET 
inhibitors could circumvent the HGF-induced hyposensitivity to irreversible 
EGFR-TKI. Our findings provide a novel insight into the involvement of 
HGF-MET-mediated signaling in acquired resistance to irreversible EGFR-TKIs 






The secondary T790M mutation in epidermal growth factor receptor (EGFR) is 
the most frequent cause of acquired resistance to the reversible EGFR tyrosine 
kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, in lung cancer. Irreversible 
EGFR-TKIs are expected to overcome the reversible EGFR-TKI-resistance of 
lung cancer harboring T790M mutation in EGFR. However, it is clear that 
resistance may also develop to this class of inhibitors. We demonstrated 
previously that hepatocyte growth factor (HGF) induced gefitinib resistance of 
lung cancer harboring EGFR-activating mutations. Here, we investigated 
whether HGF induced resistance to the irreversible EGFR-TKI, CL-387,785 in 
lung cancer cells (H1975) harboring both L858R activating mutation and T790M 
secondary mutation in EGFR. 
Experimental Design 
CL-387,785 sensitivity and signal transduction in H1975 cells were examined in 
the presence or absence of HGF or HGF-producing fibroblasts, with or without 
HGF-MET inhibitors. 
Results 
HGF reduced susceptibility to CL-387,785 in H1975 cells. Western blotting and 
siRNA analyses indicated that HGF-induced hyposensitivity was mediated by 
the MET/PI3K/Akt signaling pathway, independent of EGFR, ErbB2, ErbB3, and 
ErbB4. Hyposensitivity of H1975 cells to CL-387,785 was also induced by 
co-culture with high-level HGF-producing lung fibroblasts. The hyposensitivity 
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was abrogated by treatment with anti-HGF neutralizing antibody, HGF 
antagonist NK4, or MET-TKI. 
Conclusions 
We demonstrated HGF-mediated hyposensitivity as a novel mechanism of 
resistance to irreversible EGFR-TKIs. It will be clinically valuable to investigate 
the involvement of HGF-MET-mediated signaling in de novo and acquired 





Lung cancer is the most common cause of malignancy-related death worldwide 
and its incidence is still increasing. Non-small cell lung cancer (NSCLC) 
accounts for nearly 80% of cases of lung cancer. Median survival of metastatic 
NSCLC is 8 to 10 months even if treated with the most active combination of 
conventional chemotherapeutic agents (1, 2). Epidermal growth factor receptor 
(EGFR) activating mutations, such as deletion in exon 19 and L858R point 
mutation in exon 21(3), were found in NSCLC. These mutations are 
predominantly found in female, non-smoking, adenocarcinoma patients, and in 
patients of East Asian origin, and are associated with favorable response to the 
reversible EGFR tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib (4). 
Several prospective clinical trials showed that 70% to 75% of NSCLC patients 
with tumors harboring these mutations respond to gefitinib or erlotinib (3, 5). 
However, even patients who show a marked response to initial treatment also 
develop acquired resistance to the EGFR tyrosine kinase inhibitors almost 
without exception after varying periods (3). 
Several mechanisms, including T790M secondary mutation in EGFR (6, 
7), MET amplification (8), and overexpression of hepatocyte growth factor (HGF) 
(9), were reported to induce acquired resistance to reversible EGFR-TKI for 
NSCLC with EGFR-activating mutations. The first mechanism of acquired 
resistance described was acquisition of the T790M EGFR mutation. The 
methionine residue at position 790 generates a bulkier side chain that either 
affects binding of TKIs or enhances the affinity of the EGFR tyrosine kinase 
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pocket to ATP (7), and this enhanced ATP affinity decreases the effective binding 
of gefitinib and erlotinib to the tyrosine kinase pocket of EGFR (10). T790M in 
EGFR is found most frequently (~50%) in patients with acquired resistance to 
EGFR-TKI (7, 11). A minor population of clones with this second mutation 
(T790M) is thought to exist in the tumor before treatment and to be selected and 
expand during continuous treatment with gefitinib or erlotinib, and hence develop 
a resistant phenotype (3,12,13). Resistance mediated by secondary T790M 
mutation is thought to be manageable by irreversible EGFR inhibitors, such as 
CL-387,785, PF00299804, HKI-272, and EKB-569, which bind covalently to 
Cys-797 of EGFR (14-17). Although some of these inhibitors are in clinical 
development and early signs of success have been reported in lung cancer 
patients who were refractory to gefitinib or erlotinib (18-20), it is clear that 
resistance may also develop against this class of inhibitors. 
We recently demonstrated that HGF induces gefitinib resistance in lung 
cancer harboring EGFR-activating mutation by activating its receptor MET and 
downstream PI3K/Akt pathway. This mechanism can be involved in both intrinsic 
resistance and acquired resistance to gefitinib (9). HGF was originally identified 
as a mitogenic protein for hepatocytes and has been shown to have pleiotropic 
biological activities (21). HGF and its receptor MET are expressed at various 
levels in various types of cancer cells, including lung cancer (22–25). A recent 
study demonstrated that HGF was strongly expressed in 5 of 7 specimens with 
T790M second mutation obtained from lung cancer patients who developed 
acquired resistance to gefitinib (26), suggesting that these two resistance 
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mechanisms can coexist in lung cancer patients. 
The present study was performed to investigate whether HGF induced 
resistance to irreversible EGFR-TKI in lung cancer cells with secondary T790M 
mutation in EGFR. We assessed this issue using an irreversible EGFR-TKI, 
CL-387,785, and human lung cancer cells, H1975, harboring both L858R and 
T790M mutations in EGFR. We found that HGF reduced susceptibility to 
CL-387,785 in H1975 cells by stimulating the MET/Akt pathway. The resistance 
was also induced by crosstalk to HGF-producing fibroblast cell lines as well as 
primary cultured fibroblasts established from lung cancer patients. We further 
demonstrated that HGF-MET inhibitors could circumvent the HGF-induced 
hyposensitivity to irreversible EGFR-TKI. 
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Materials and methods 
Cell lines and reagents 
The H1975 human lung adenocarcinoma cell line with EGFR L858R/T790M 
double mutation (10) was kindly provided by Dr. John D. Minna (University of 
Texas Southwestern Medical Center, Dallas, TX). The PC-9 and HCC827 human 
lung adenocarcinoma cell lines with EGFR-activating mutation (deletion in exon 
19) were purchased from Immuno-Biological Laboratories Co. (Takasaki, Gunma, 
Japan) and American Type Culture Collection (Manassas, VA), respectively. The 
MRC-5 lung embryonic fibroblast cell line was obtained from RIKEN Cell Bank. 
H1975, PC-9, and HCC827 cells were cultured in RPMI 1640 medium and 
MRC-5 (P 30-35) cells were cultured in DMEM, supplemented with 10% fetal 
bovine serum (FBS), penicillin (100 U/mL), and streptomycin (50 µg/mL), in a 
humidified CO2 incubator at 37°C. All experiments were performed in medium 
supplemented with 10% FBS. 
Gefitinib was obtained from AstraZeneca (Cheshire, UK). Erlotinib hydrochloride 
was obtained from Roche Pharma AG (Basel, Switzerland). CL-387,785 and 
SU-11274 were purchased from Calbiochem (San Diego, CA). Cetuximab was 
purchased from Merck Serono (Darmstadt, Germany). Recombinant HGF and 
NK4 were prepared as reported previously (22, 27, 28). The purities of NK4 and 
HGF were 96.4% and > 98%, respectively, as determined by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and protein staining. 
Recombinant epidermal growth factor (EGF) and insulin-like growth factor I 
(IGF-I) were obtained from Invitrogen (Carlsbad, CA). Transforming growth 
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factor α (TGF-α) was from BioSource (San Jose, CA). Goat anti-human HGF 
neutralizing antibody, monoclonal anti-human EGF neutralizing antibody, goat 
anti-human TGF-α neutralizing antibody, and control goat IgG were purchased 
from R&D Systems (Minneapolis, MN). 
 
Isolation of fibroblasts from lung cancer tissue 
Primary cultured fibroblasts were established from surgically resected tumors 
from patients with histologically proven lung cancer at Kanazawa University 
Hospital, as described previously (29). The protocol was approved by the 
Medical Ethical Committee of Kanazawa University. Written informed consent 
was obtained from all patients. To establish primary fibroblasts, fresh lung cancer 
tissues from patients were minced with a scalpel in tissue culture dishes, 
digested with trypsin, and passed though a cell strainer. The resulting 
suspensions were incubated in RPMI1640 supplemented with 10% FBS, 
penicillin, and streptomycin. After 48 hours, unattached cells were removed and 
the medium was replaced with fresh medium. After 7 to 10 days, the cells formed 
a homogenous monolayer morphologically consistent with fibroblast-like cells, 
which were confirmed to consist of > 90% type I collagen-positive cells. 
 
Cell proliferation assay 
Cell proliferation was measured using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT) dye reduction 
method (30). Tumor cells at 80% confluence were harvested, seeded at 2 × 103 
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cells per well in 96-well plates, and incubated in RPMI 1640 with 10% FBS. After 
24 hours of incubation, several concentrations of gefitinib, erlotinib, CL-387,785, 
goat anti-human HGF neutralizing antibody, control goat IgG, NK4, SU-11274, 
and/or cytokines were added to each well, and incubation was continued for a 
further 72 hours. Then, an aliquot of 50 μL of MTT solution (2 mg/mL; Sigma, St. 
Louis, MO) was added to each well followed by incubation for 2 hours at 37°C. 
The media were removed and the dark blue crystals in each well were dissolved 
in 100 μL of DMSO. Absorbance was measured with an MTP-120 microplate 
reader (Corona Electric, Ibaraki, Japan) at test and reference wavelengths of 
550 nm and 630 nm, respectively. The percentage of growth is shown relative to 
untreated controls. Each experiment was performed at least in triplicate, and 
three times independently. 
 
Immunoprecipitation and Western blotting 
Tumor cells were incubated in 10 mL of RPMI 1640 with 10% FBS in the 
presence or absence of HGF and/or CL-387,785. Then, cells were washed twice 
with PBS, harvested in cell lysis buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM 
β-glycerophosphate, 1 mM Na3VO4, 1 μg/mL leupeptin, and 1 mM 
phenylmethylsulfonyl fluoride), and flash-frozen on dry ice. After allowing the 
cells to thaw, the cell lysates were collected with a rubber scraper, sonicated, 
and centrifuged at 14000 × g (4°C for 20 min). The total protein concentration 
was measured using a Pierce BCA Protein Assay Kit (Pierce, Rockford, IL). 
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Aliquots of 500 μg of total proteins were immunoprecipitated with the appropriate 
antibodies. Immune complexes were recovered with Protein G-Sepharose beads 
(Zymed Laboratories, San Francisco, CA). For Western blotting assay, 
immunoprecipitates or cell lysates were subjected to SDS-PAGE (Bio-Rad, 
Hercules, CA) and the proteins were then transferred onto polyvinylidene 
difluoride membranes (Bio-Rad). The membranes were blocked with Blocking 
One (Nacalai Tesque, Kyoto, Japan) for 1 hour at room temperature, and the 
blots were then incubated at 4°C overnight with anti-Met (25H2), 
anti-phospho-Met (Y1234/Y1235) (3D7), anti-ErbB2(29D8), anti-ErbB3 (1B2), 
anti-ErbB4(111B2), anti-phospho-EGFR (Y1068), anti-phospho-EGFR (Y1086), 
anti-phospho-ErbB2(Tyr1221/1222)(6B12), anti-phospho-ErbB3 (Tyr1289) 
(21D3), anti-phospho-ErbB4(Tyr1284)(21A9), PI3K p85 (19H8), anti-Akt, or 
anti-phospho-Akt (Ser473) antibodies (1:1000 dilution; Cell Signaling Technology, 
Danvers, MA), and anti-human EGFR (1 μg/mL), anti-human/mouse/rat 
extracellular signal-regulated kinase (ERK)1/ERK2 (0.2 μg/mL), or 
anti-phospho-ERK1/ERK2 (T202/Y204) (0.1 μg/mL) antibodies (R&D Systems, 
Minneapolis, MN). After washing three times, the membranes were incubated for 
1 hour at room temperature with secondary Ab (horseradish 
peroxidase-conjugated species-specific Ab). Immunoreactive bands were 
visualized with SuperSignal West Dura Extended Duration Substrate Enhanced 
Chemiluminescent Substrate (Pierce). Each experiment was performed at least 





Duplexed Stealth RNAi (Invitrogen) against MET, EGFR, and ErbB3 and Stealth 
RNAi Negative Control Low GC Duplex #3 (Invitrogen) were used for RNA 
interference (RNAi) assay. Briefly, aliquots of 1 × 105 H1975 cells in 2 mL of 
antibiotic-free medium were plated on 6-well plates and incubated at 37°C for 24 
hours. The cells were then transfected with siRNA (250 pmol) or scramble RNA 
(siSCR) using Lipofectamine 2000 (5 μL) in accordance with the manufacturer’s 
instructions (Invitrogen). After 24 hours, the cells were washed twice with PBS, 
and incubated with or without CL-387,785 (300 nM) and/or recombinant human 
HGF (50 ng/mL) for an additional 72 hours in antibiotic-containing medium. 
These cells were then used for proliferation assay as described above. MET, 
EGFR, and ErbB3 knockdown were confirmed by Western blotting analysis. The 




5'-CGGAAUAGGUAUUGGUGAAUUUAAA -5'; ErbB3, 
5'-GGCCAUGAAUGAAUUCUCUACUCUA-3' and 
5'-UAGAGUAGAGAAUUCAUUCAUGGCC-3'. Each experiment was performed 
at least in triplicate, and three times independently. 
 
HGF production in cell culture supernatant 
Cells (2 x 105) were cultured in 2 mL of RPMI 1640 or DMEM with 10% FBS for 
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24 hours. The cells were washed with PBS and incubated for 48 hours in RPMI 
1640 or DMEM with 10% FBS, with or without various concentrations of 
CL-387,785. The culture medium was then harvested and centrifuged, and the 
supernatant was stored at –70°C until analysis. For determination of HGF, ELISA 
was performed in accordance with the manufacturer’s recommended 
procedures (Immunis HGF EIA; B-Bridge International, Mountain View, CA). All 
samples were run in triplicate. Color intensity was measured at 450 nm with a 
spectrophotometric plate reader. Growth factor concentrations were determined 
by comparison with standard curves. The detection limit was 0.1 ng/mL. 
 
Co-culture of lung cancer cells with fibroblasts 
The co-culture system was performed using Transwell chambers separated by 
an 8-μm pore size filter. Tumor cells (8 × 103 cells/700 μL) with or without 
CL-387,785 (300 nM) in the lower chamber were co-cultured with fibroblasts (104 
cells/300 μL) with or without 2 hours of pretreatment with control IgG (2 μg/mL), 
anti-HGF neutralizing antibody (2 μg/mL), anti-EGF neutralizing antibody (2 
μg/mL), or anti-TGF-α neutralizing antibody (2 μg/mL) in the upper chamber for 
72 hours. The upper chamber was then removed and 200 μL of MTT solution (2 
mg/mL; Sigma) was added to each well and the cells were incubated for 2 hours 
at 37°C. The media were removed and the dark blue crystals in each well were 
dissolved in 400 μL of DMSO. Absorbance was measured with an MTP-120 
microplate reader (Corona Electric) at test and reference wavelengths of 550 nm 
and 630 nm, respectively. The percentage of growth is shown relative to 
untreated controls. Each experiment was performed at least in triplicate, and 
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three times independently. 
 
Statistical analysis 
All data, expressed as means ± SE, were analyzed by Mann-Whitney U-test, 
and P < 0.05 was considered to indicate statistical significance. All statistical 




HGF induced hyposensitivity to irreversible EGFR-TKI, CL-387,785, in lung 
cancer cells with EGFR-L858R/T790M mutations 
We first examined the effects of the reversible EGFR-TKI, gefitinib and erlotinib, 
and irreversible EGF-TKI, CL-387,785, against H1975 cells harboring L858R 
activating mutation and T790M second mutation in EGFR (11). H1975 cells were 
highly sensitive to CL-387,785 (IC50 0.24 μM), while they were resistant to 
gefitinib and erlotinib, as reported previously (Fig. 1A)(14, 31). HGF (50 ng/mL) 
alone had no effect on the proliferation of H1975 cells as well as PC-9 and 
HCC827cells with activating mutation in EGFR. Under these experimental 
conditions, HGF (50 ng/mL) reduced the degrees of susceptibility of H1975 (IC50 
0.48 μM), PC-9, and HCC827 cells to CL-387,785 (Fig. 1B, S1). The effect of 
HGF in H1975 cells was abrogated by anti-HGF neutralizing antibody (2 μg/mL) 
but not control IgG (2 μg/mL) (Fig. 1C). 
We also examined the effects of other cytokines, including EGF (32), 
TGF-α (33), and IGF-I (34), reported to be related to EGFR-TKI sensitivity. 
Although EGF and TGF-α tended to induce hyposensitivity of H1975 cells to 
CL-387,785, HGF showed the strongest effect in induction of hyposensitivity to 
CL-387,785 in H1975 cells (Fig. 2). 
 
HGF-induced CL-387,785 hyposensitivity was mediated by restoring 
phosphorylation of Akt and ERK1/2, but not EGFR or ErbB3 
To investigate the molecular mechanism by which HGF induces CL-387,785 
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hyposensitivity, we examined the protein expression and phosphorylation status 
of MET, ErbB family proteins, and downstream molecules by Western blotting. 
H1975 cells expressed EGFR, ErbB2, ErbB3, ErbB4, MET, and PI3K-P85 
proteins. Of these, EGFR, ErbB3, and MET were phosphorylated at various 
levels, but neither ErbB2 nor ErbB4 was phosphorylated in H1975 cells under 
our experimental conditions. Akt and ERK1/2, the downstream molecules of 
these receptors, were also phosphorylated. CL-387,785 inhibited the 
phosphorylation of EGFR, ErbB3, Akt, and ERK1/2, but not MET, showing the 
selectivity of this compound to the EGFR family. HGF alone stimulated 
phosphorylation of not only MET, Akt, and ERK1/2 but also EGFR and ErbB3. In 
the presence of HGF, CL-387,785 inhibited the phosphorylation of EGFR but did 
not affect phosphorylation of Akt or ERK1/2 (Fig. 3A). 
To investigate the mechanism in detail, we immunoprecipitated MET and 
examined the association with PI3K-related molecules. In H1975 cells, MET was 
constitutively associated with p85, the binding domain of PI3K, and this 
association was unaffected by CL-387,785 and/or HGF. MET was slightly 
associated with ErbB3, and this association was also unaffected by CL-387,785 
and/or HGF. On the other hand, MET was constitutively associated with EGFR, 
and this association was augmented by HGF. Importantly, CL-387,785 disrupted 
association of MET-EGFR, irrespective of the presence or absence of HGF (Fig. 
3B). These results suggest that in the absence of EGFR inhibition, some if not all 
MET protein is associated with EGFR and HGF stimulates MET-EGFR 
association and downstream signaling (Akt and ERK 1/2). In contrast, in the 
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presence of EGFR inhibition, MET may show reduced association with 
inactivated EGFR. Therefore, HGF may stimulate Akt and ERK1/2 signaling 
predominantly via MET under these conditions.  
 
Specific down-regulation of MET, but not EGFR or ErbB3, reversed 
CL-387,785 hyposensitivity and phosphorylation of Akt and ERK1/2 
induced by HGF 
To clarify the involvement of MET, EGFR, and ErbB3, we further down-regulated 
MET, EGFR, and ErbB3 expression, respectively, with specific siRNAs using 
H1975 cells. Down-regulation of EGFR, but not MET or ErbB3, resulted in 
reduced viability of H1975 cells, similar to irreversible EGFR-TKI treatment, 
suggesting the importance of EGFR in viability of H1975 cells. Down-regulation 
of EGFR or ErbB3 did not affect either HGF-induced hyposensitivity to 
CL-387,785 or phosphorylation of Akt and ERK1/2 restored by HGF in H1975 
cells. In parallel experiments, down-regulation of MET expression by 
MET-specific siRNA canceled HGF-induced hyposensitivity to CL-387,785, as 
well as phosphorylation of Akt and ERK1/2 restored by HGF (Fig. 4). These 
results indicate that HGF induces CL-387,785 hyposensitivity by activating the 
Akt and ERK1/2 signaling pathway via MET phosphorylation. 
 
Fibroblast-derived HGF induced CL-387,785 hyposensitivity in lung cancer 
cells 
It is well documented that host microenvironments can affect the 
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chemosensitivity of cancers and that stromal fibroblasts are the major source of 
HGF (35). We next examined the production of HGF by three human fibroblast 
cell lines and fibroblasts in primary culture established from the tumors of five 
different lung cancer patients. Our observations indicated that levels of HGF 
production by these fibroblasts varied and that the human embryonic 
lung-derived fibroblasts, MRC-5, and the primary culture fibroblasts from patient 
2 (PF2) produced high levels of HGF in their supernatants. On the other hand, 
H1975 cells did not produce detectable levels of HGF in the culture supernatant 
with or without various concentrations of CL-387,785 (Fig. 5A, S2). To further 
investigate whether the susceptibility of H1975 cells to CL-387,785 could be 
affected by crosstalk to stromal fibroblasts, we co-cultured the H1975 cells with 
MRC-5 cells or PF2, using Transwell systems. While H1975 cells were highly 
sensitive to CL-387,785, exogenously added HGF induced CL-387,785 
hyposensitivity of H1975 cells as mentioned above. Co-culture with MRC-5 or 
PF2 cells did not significantly affect the proliferation of H1975 cells. Under these 
experimental conditions, H1975 cells became hyposensitive to CL-387,785 in 
the presence of MRC-5 or PF2 cells. This was abrogated by treatment with 
anti-HGF neutralizing antibody (2 μg/mL), but not the neutralizing antibodies 
against EGF (2 μg/mL) or TGF-α (2 μg/mL) (Fig. 5B, S3). These results indicate 
that fibroblast-derived HGF could induce CL-387,785 hyposensitivity of lung 
cancer cells with EGFR-L858R/T790M mutations. 
 




Recently, several inhibitors of HGF-MET signaling have been developed. 
Therefore, to establish the novel therapeutic modality against HGF-mediated 
resistance to irreversible EGFR-TKI, we treated H1975 cells with CL-387,785 in 
combination with anti-HGF neutralizing antibody, HGF antagonist, or MET 
tyrosine kinase inhibitor (MET-TKI). The MET-TKI, SU11274, moderately 
reversed the HGF-induced CL-387,785 hyposensitivity at the non-toxic 
concentration of 1 μM. Both anti-HGF neutralizing antibody (2 μg/mL) and HGF 
antagonist, NK4 (300 nM), completely abrogated the CL-387,785 hyposensitivity 
at non-toxic concentrations (Fig. 6), suggesting the promising potential of these 




In the present study, we demonstrated that HGF reduced susceptibility to an 
irreversible EGFR-TKI, CL-387,785, in human lung cancer cells harboring a 
secondary T790M mutation. HGF-induced CL-387,785 hyposensitivity was 
mediated by activation of the PI3K/Akt pathway via phosphorylation of MET, 
independent of EGFR, ErbB2, ErbB3, or ErbB4. The reduced susceptibility was 
also caused by co-culture with an HGF-producing fibroblast cell line as well as 
primary cultured fibroblasts established from a lung cancer patient. In addition, 
HGF-MET inhibitors could circumvent the HGF-induced hyposensitivity to 
irreversible EGFR-TKI. 
H1975 is a human lung adenocarcinoma cell line, which has both L858R 
and T790M as an activating mutation and secondary resistance mutation, 
respectively, in EGFR. This cell line is widely used as a model to develop novel 
targeting drugs, including irreversible EGFR-TKI, which overcome 
T790M-mediated drug resistance (14, 15). More recently, this cell line was also 
used to identify a novel mechanism of resistance to irreversible EGFR-TKI. Yu et 
al. carried out a cell-based in vitro random mutagenesis screen to identify an 
EGFR mutation that induced resistance to CL-387,785 (15). They found several 
mutations in EGFR that induced resistance to CL-387,785 in H1975 cells, 
although the mechanisms by which these mutations caused resistance remained 
unclear. In the present study, we demonstrated another mechanism showing that 
HGF reduced susceptibility to CL-387,785 in this cell line by activating the MET/ 
PI3K/Akt pathway to send a survival signal. In addition, HGF-induced 
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CL-387,785 hyposensitivity was also observed in PC-9 and HCC827 cells, which 
had EGFR-activating mutation (deletion in exon 19) alone. Lung cancer cells 
with EGFR-activating mutations, with or without T790M mutation, seem to be 
dependent on the signal from the mutated EGFR for their survival (36). 
Therefore, an alternative signal pathway via MET may be important for their 
survival when the EGFR signal is blocked by inhibitors. In fact, Tang et al. 
demonstrated the efficacy of dual receptor tyrosine kinase-targeted inhibition 
against MET (SU11274) and EGFR (erlotinib or CL-387,785) as a strategy to 
achieve optimized inhibition in T790M-EGFR-mediated erlotinib resistance (37). 
To overcome T790M mutation-mediated resistance, several agents, 
such as irreversible EGFR-TKIs, anti-EGFR antibody (38), and Hsp90 inhibitors 
(39), have been developed and evaluated with regard to their efficacy in 
pre-clinical and clinical trials. Of the irreversible EGFR-TKIs, PF00299804, 
HKI-272, EKB-569, and BIBW2992 are currently in clinical trials, while 
commercially available CL-387,785 is not (19, 40). Yoshimura et al. reported 
promising results showing that EKB-569 caused partial responses in 2 cases of 
lung cancer that acquired resistance during treatment with reversible EGFR-TKI, 
gefitinib (18). Other groups also reported early signs of success with HKI-272 
and PF00299804 in gefitinib- or erlotinib-refractory cancers (19, 20). Anti-EGFR 
chimeric antibody, cetuximab, has also been reported to block the downstream 
signal of EGFR and potently induce antibody-dependent cellular cytotoxicity 
(ADCC), and thus show antitumor activity against several cell lines, including 
H1975 (38). However, even though these agents show favorable responses in 
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tumors with T790M mutation, it is clear that resistance can also develop against 
this class of inhibitors. We demonstrated that HGF could induce hyposensitivity 
to irreversible EGFR-TKI. In addition, our preliminary experiments indicated that 
while cetuximab inhibited the growth of H1975 cells, HGF caused hyposensitivity 
to cetuximab (data not shown). Thus, it may be useful to investigate the 
involvement of HGF-MET-mediated signaling in acquired resistance to 
irreversible EGFR-TKIs as well as anti-EGFR antibody in lung cancer harboring 
T790M mutation in EGFR. 
MET is known to be only one specific receptor for HGF (41, 42). MET 
activated by HGF binding forms a homodimer and transduces strong signals to 
various pathways, including PI3K/Akt, MAPK/ERK, and STAT (43). MET is also 
known to form heterodimers with other growth receptors, including EGFR and 
ErbB3 (8). Engelman et al. reported that amplified MET associated with ErbB3 
and caused gefitinib resistance in lung cancer cells (8). Recent reports further 
indicated the important interaction between MET and EGFR (44, 45). These two 
receptors mediate collaborative signaling with receptor cross-activation (43). 
However, direct interaction between MET and EGFR with T790M mutation has 
not been reported previously. In the present study, we found that MET directly 
associated with EGFR harboring T790M mutation in H1975 cells, and that this 
association was enhanced by HGF resulting in augmented phosphorylation of 
Akt and ERK1/2. These observations indicate that MET interacts closely with 
EGFR harboring T790M mutation and regulates these important signal pathways. 
Therefore, simultaneous inhibition of MET and EGFR with T790M mutation may 
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be useful not only for overcoming HGF-induced TKI resistance, but also for 
controlling the progression of TKI-naïve tumors with T790M mutation in EGFR. 
Although we could not perform in vivo experiments in this study because of the 
limited availability of CL-387,785, further in vivo experiments are warranted to 
assess the therapeutic effects of irreversible EGFR-TKI combined with 
HGF-MET inhibitors. 
The tumor microenvironment is important for tumor progression and 
drug sensitivity (46). Fibroblastic stromal cells have been linked to several 
activities that promote tumor progression, including angiogenesis, epithelial to 
mesenchymal transition, progressive genetic instability, and deregulation of 
antitumor immune responses, enhanced metastasis, and prevention of 
apoptosis induced by chemotherapeutic agents. Stromal fibroblasts are one of 
the major sources of various cytokines, including HGF (35). In the present study, 
we confirmed that fibroblast cell lines and primary cultured fibroblasts produced 
various levels of HGF and irreversible EGFR-TKI-hyposensitivity could be 
induced by HGF derived from both fibroblast cell lines and primary cultured 
fibroblasts by a paracrine mechanism. Therefore, it is possible that 
tumor-associated fibroblasts are involved in resistance to irreversible EGFR-TKI 
in lung cancer patients harboring EGFR T790M mutation. 
In summary, we reported a novel mechanism of resistance to irreversible 
EGFR-TKI in lung cancer harboring secondary T790M mutation in EGFR. HGF 
induced hyposensitivity to the irreversible EGFR-TKI, CL-387,785, by activating 
the PI3K/Akt pathway via phosphorylation of MET independent of EGFR family 
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proteins. The hyposensitivity was also induced by co-culture with 
HGF-producing fibroblasts, suggesting the possible involvement of 
microenvironments in resistance to irreversible EGFR-TKIs. Moreover, we 
demonstrated that HGF-MET inhibitors could circumvent the HGF-induced 
hyposensitivity to irreversible EGFR-TKI. Therefore, it will be clinically valuable 
to investigate the involvement of HGF-MET-mediated signaling in acquired 






1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy 
regimens for advanced non-small-cell lung cancer. N Engl J Med 
2002;346:92–8. 
 
2. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus 
irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and 
cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm 
Cooperative Study in Japan. Ann Oncol 2007;18:317–23. 
 
3. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor 
gene and related genes as determinants of epidermal growth factor receptor 
tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 
2007;98:1817–24. 
 
4. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features 
associated with epidermal growth factor receptor gene mutations in lung cancers. 
J Natl Cancer Inst 2005;97:339–46. 
 
5. Inoue A, Suzuki T, Fukuhara T et al. Prospective phase II study of gefitinib for 
chemotherapy-naive patients with advanced non-small-cell lung cancer with 




6. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary 
T790M mutations in epidermal growth factor receptor-mutant lung 
adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 
2006;12:6494–501. 
 
7. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of 
non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–92. 
 
8. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to 
gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 
2007;316:1039–43. 
 
9. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib 
resistance of lung adenocarcinoma with epidermal growth factor 
receptor–activating mutations. Cancer Res 2008;68:9479–87. 
 
10. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR 
kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad 
Sci U S A 2008;105:2070–5. 
 
11. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung 
adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in 
28 
 
the EGFR kinase domain. PLoS Med 2005;2:225–35. 
 
12. Toyooka S, Kiura K, Mitsudomi T. EGFR mutation and response of lung 
cancer to gefitinib. N Engl J Med 2005;352:2136. 
 
13. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures 
detection of a biologically significant resistance mutation in EGFR-amplified lung 
cancer. J Clin Invest 2006;116:2695-706. 
 
14. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B. 
An alternative inhibitor overcomes resistance caused by a mutation of the 
epidermal growth factor receptor. Cancer Res 2005;65:7096–101. 
 
15. Yu Z, Boggon TJ, Kobayashi S, et al. Resistance to an irreversible epidermal 
growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals 
novel treatment strategies. Cancer Res 2007;67:10417–27. 
 
16. Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible 
pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 
mutations that are resistant to gefitinib. Cancer Res 2007;67:11924–32. 
 
17. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF 





18. Yoshimura N, Kudoh S, Kimura T, et al. EKB-569, a new irreversible 
epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in 
patients with non-small cell lung cancer with acquired resistance to gefitinib. 
Lung Cancer 2006;51:363–8. 
 
19. Jänne PA, Schellens JH, Engelman JA, et al. Preliminary activity and safety 
results from a phase I clinical trial of PF-00299804, an irreversible pan-HER 
inhibitor, in patients (pts) with NSCLC. J Clin Oncol 2008;26:S20 (abstr 8027) 
 
20. Wong KK, Fracasso PM, Bukowski RM, et al. A phase I study with neratinib 
(HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients 
with solid tumors. Clin Cancer Res 2009;15:2552-8. 
 
21. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and 
expression of human hepatocyte growth factor. Nature 1989;342:440–3. 
 
22. Guo A, Villén J, Kornhauser J, et al. Signaling networks assembled by 
oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 2008;105:692–7. 
 
23. Nakamura Y, Niki T, Goto A, et al. c-Met activation in lung adenocarcinoma 




24. Masuya D, Huang C, Liu D, et al. The tumour-stromal interaction between 
intratumoral c-Met and stromal hepatocyte growth factor associated with tumour 
growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 
2004;90:1555-62. 
 
25. Ma PC, Tretiakova MS, MacKinnon AC, et al. Expression and mutational 
analysis of MET in human solid cancers. Genes Chromosomes Cancer 
2008;47:1025-37. 
 
26. Onitsuka T, Uraoto H, Nose N, et al. Acquired resistance to gefitinib: the 
contribution of mechanisms other than the T790M, MET, and HGF status. Lung 
Cancer 2009, in press. 
 
27. Seki T, Ihara I, Sugimura A, et al. Isolation and expression of cDNA for 
different forms of hepatocyte growth factor from human leukocytes, Biochem 
Biophys Res Commun 1990;172: 321–7. 
 
28. Tomioka D, Maehara N, Kuba K, et al. Inhibition of growth, invasion, and 
metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse 
model. Cancer Res 2001;61: 7518–24. 
 
29. Barker SE, Grosse SM, Siapati EK et al. Immunotherapy for neuroblastoma 
using syngeneic fibroblasts transfected with IL-2 and IL-12. Br J Cancer 
2007;97:210–7. 
 
30. Green LM, Reade JL, Ware CF. Rapid colorimetric assay for cell viability: 
application to the quantitation of cytotoxic and growth inhibitory lymphokines. J 
Immunol Methods 1984;70:257–68. 
 
31. de La Motte Rouge T, Galluzzi L, Olaussen KA, et al. A novel epidermal 
growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer 
cells resistant to erlotinib. Cancer Res 2007;67:6253–62. 
 
32. Wu W, O'Reilly MS, Langley RR, et al. Expression of epidermal growth factor 
(EGF)/transforming growth factor-α by human lung cancer cells determines their 
response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol 
Cancer Ther 2007;6:2652–63. 
 
33. Ishikawa N, Daigo Y, Takano A, et al. Increases of amphiregulin and 
transforming growth factor-  in serum as predictors of poor response to gefitinib 
among patients with advanced non-small cell lung cancers. Cancer Res 
2005;65:9176–84. 
 





the insulin-like growth factor-IR pathway in the resistance of non-small cell lung 
cancer cells to treatment with gefitinib. Clin Cancer Res 2007;13:2795–803. 
 
35. Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system as 
a mediator of tumor-stromal interactions. Int J Cancer 2006;119:477–83.  
 
36. Godin-Heymann N, Bryant I, Rivera MN, et al. Oncogenic activity of 
epidermal growth factor receptor kinase mutant alleles is enhanced by the 
T790M drug resistance mutation. Cancer Res 2007;67:7319–26. 
 
37. Tang Z, Du R, Jiang S, et al. Dual MET-EGFR combinatorial inhibition 
against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 
2008;99:911–22. 
 
38. Steiner P, Joynes C, Bassi R, et al. Tumor growth inhibition with cetuximab 
and chemotherapy in non-small cell lung cancer xenografts expressing wild-type 
and mutated epidermal growth factor receptor. Clin Cancer Res 
2007;13:1540–51. 
 
39. Shimamura T, Li D, Ji H, et al. Hsp90 inhibition suppresses mutant 





40. Riely GJ. Second-generation epidermal growth factor receptor tyrosine 
kinase inhibitors in non-small cell lung cancer. J Thorac Oncol 2008;3:S146–9. 
 
41. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte 
growth factor receptor as the c-met proto-oncogene product. Science 
1991;251:802–4. 
 
42. Naldini L, Vigna E, Narsimhan RP, et al. Hepatocyte growth factor (HGF) 
stimulates the tyrosine kinase activity of the receptor encoded by the 
proto-oncogene c-MET. Oncogene 1991;6:501–4. 
 
43. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic 
programme for cancer and stem cells. Nat Rev Cancer 2006;6:637–45. 
 
44. Han C, Michalopoulos GK, Wu T. Prostaglandin E2 receptor EP1 
transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness 
in human hepatocellular carcinoma cells. J Cell Physiol 2006;207:261–70. 
 
45. Kubo T, Yamamoto H, Lockwood WW, et al. MET gene amplification or 
EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine 
kinase inhibitors. Int J Cancer. 2009;124:1778–84. 
 
46. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation 
34 
 






HGF induced CL-387,785 hyposensitivity of lung adenocarcinoma cells 
with EGFR-L858R/T790M mutations. 
(A) H1975 cells were highly sensitive to CL387,785 (IC50 300nM), and were 
resistant to gefitinib and erlotinib. Tumor cells were incubated with increasing 
concentrations of CL-387,785, gefitinib, or erlotinib and cell growth was 
determined after 72 hours of treatment by MTT assay. 
(B) HGF induced CL-387,785 hyposensitivity of H1975 cells with 
EGFR-L858R/T790M mutation. Tumor cells were incubated with increasing 
concentrations of CL-387,785 and/or HGF at 50 ng/mL, and cell growth was 
determined in the same way as in A.  
(C) Pretreatment of HGF with anti-HGF antibody abrogated HGF-induced 
hyposensitivity of H1975 cells to CL-387,785. HGF (50 ng/mL) was pretreated 
with control IgG (2 µg/mL) or anti-HGF antibody (2 µg/mL) at 37°C for 1 hour. 
The resultant solutions were added to the cultures of tumor cells with or without 
CL-387,785 (300 nM). Cell growth was determined in the same way as in A. *, P 
< 0.01 (Mann-Whitney U test). 
 
Figure 2 




H1975 cells were incubated with or without CL-387,785 and/or 50 ng/mL of HGF, 
EGF, TGF-α, or IGF-I. Cell growth was determined after 72 hours of treatment. 
The percentage of growth is shown relative to untreated controls. *, P < 0.05 
(Mann-Whitney U test). 
 
Figure 3 
HGF induces CL-387,785 hyposensitivity of lung adenocarcinoma cells 
with EGFR-T790M mutation by restoring phosphorylation of Akt and 
ERK1/2, but not EGFR and ErbB3. 
(A) CL-387,785 inhibited the phosphorylation of EGFR but did not affect 
phosphorylation of Akt and ERK1/2 in the presence of HGF. Tumor cells were 
treated with or without CL-387,785 (300 nM) and/or HGF (50 ng/mL) for 1 hour. 
Cells were lysed, and the indicated proteins were detected by immunoblotting. 
(B) Cell extracts were immunoprecipitated with an antibody to MET. The 




Specific down-regulation of MET, but not EGFR and ErbB3, reversed 
CL-387,785 hyposensitivity and phosphorylation of Akt and ERK1/2 
induced by HGF. 
(A) siRNA specific for MET, but not for EGFR or ErbB3, reversed CL-387,785 
hyposensitivity by HGF. Control, MET-specific, EGFR-specific, or ErbB3-specific 
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siRNAs were introduced into H1975 cells. The growth of cells with or without 
CL-387,785 (300 nM) and/or HGF (50 ng/mL) was measured by MTT assay. *, P 
< 0.01 (Mann-Whitney U test). 
(B) Down-regulation of MET, but not EGFR and ErbB3, by specific-siRNA 
inhibited restored Akt and ERK1/2 phosphorylation by HGF in cells treated with 
CL-387,785. Control, MET-specific, EGFR-specific, or ErbB3-specific siRNAs 
were introduced into H1975 cells. After 48 hours, the cells were treated with or 
without CL-387,785 (300 nM) and/or HGF (50 ng/mL) for 1 hour, and then cell 
extracts were prepared and immunoblotted with the indicated antibodies. 
 
Figure 5 
Fibroblast-derived HGF induces CL-387,785 hyposensitivity in lung cancer 
cells with EGFR-T790M mutations. 
(A) HGF production by lung cancer cell line (H1975), human embryonic lung 
fibroblasts (MRC-5), and primary cultured fibroblasts from the tumor of lung 
cancer patient 2 (PF2). The cells were incubated in medium for 48 hours, the 
culture supernatants were harvested, and their HGF concentrations were 
determined by ELISA. 
(B) Co-culture with fibroblasts induced CL-387,785 hyposensitivity in lung 
cancer cells. The lung cancer H1975 cell line was co-cultured with MRC-5 or 
PF2 cells, with medium, anti-HGF neutralizing antibody (2 μg/mL) in the 
presence or absence of CL-387,785 (300 nM) for 72 hours, and lung cancer cell 
growth was determined after 72 hours of treatment by MTT assay. *, P < 0.01 
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(Mann-Whitney U test). 
 
Figure 6 
Anti-HGF antibody, NK4, or SU11274 abrogated HGF induced CL-387,785 
hyposensitivity in lung cancer cells with EGFR-T790M mutation. 
H1975 cells were treated for 72 hours with or without CL-387,785 (300 nM) 
and/or HGF (50 ng/mL) in the presence or absence of anti-HGF neutralizing 
antibody (2 μg/mL), NK4 (300 nM), or SU11274 (1 μM). Cell growth was 
determined by MTT assay. *, P < 0.01 (Mann-Whitney U test). 
 
Supplemental Figure 1 
HGF induced CL-387,785 hyposensitivity of lung adenocarcinoma cells 
with EGFR-L858R/T790M mutations. 
HGF induced CL-387,785 hyposensitivity of PC-9 and HCC827 cells with 
EGFR-activating mutation (deletion in exon 19). Tumor cells were incubated with 
increasing concentrations of CL-387,785 and/or HGF at 50 ng/mL, and cell 
growth was determined in the same way as described in Figure 1-A. *, P < 0.05 
vs. medium alone (Mann-Whitney U test). 
 
Supplemental Figure 2 
CL-387,785 did not affect HGF production in lung cancer cells with 
EGFR-T790M mutations. 
HGF production by the lung cancer cell line H1975 with or without various doses 
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(0.03, 0.1, 0.3 μM) of CL-387,785, and human embryonic lung fibroblasts 
(MRC-5). The cells were incubated in medium for 48 hours, the culture 
supernatants were harvested, and their HGF concentrations were determined by 
ELISA. 
 
Supplemental Figure 3 
Fibroblast-derived HGF, but not EGF or TGF-α, induces CL-387,785 
hyposensitivity in lung cancer cells with EGFR-T790M mutations. 
Co-culture with fibroblasts induced CL-387,785 hyposensitivity in lung cancer 
cells. The lung cancer H1975 cell line was co-cultured with MRC-5 cells, with 
medium, anti-HGF neutralizing antibody (2 μg/mL), anti-EGF neutralizing 
antibody (2 μg/mL), or anti-TGF-α neutralizing antibody (2 μg/mL) in the 
presence or absence of CL-387,785 (300 nM) for 72 hours, and lung cancer cell 
growth was determined after 72 hours of treatment by MTT assay. *, P < 0.01 
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